Compass Pathways PLC
NASDAQ:CMPS
Compass Pathways PLC
Stock-Based Compensation
Compass Pathways PLC
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Stock-Based Compensation
$19.5m
|
CAGR 3-Years
31%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Stock-Based Compensation
$33.6m
|
CAGR 3-Years
31%
|
CAGR 5-Years
169%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Stock-Based Compensation
$38.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Stock-Based Compensation
£37.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Stock-Based Compensation
£3.7m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
26%
|
|
Compass Pathways PLC
Glance View
Compass Pathways Plc functions as an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 116 full-time employees. The company went IPO on 2020-09-18. The firm is focused on treatment-resistant depression (TRD). The company is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.
See Also
What is Compass Pathways PLC's Stock-Based Compensation?
Stock-Based Compensation
19.5m
USD
Based on the financial report for Dec 31, 2024, Compass Pathways PLC's Stock-Based Compensation amounts to 19.5m USD.
What is Compass Pathways PLC's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
43%
Over the last year, the Stock-Based Compensation growth was 13%. The average annual Stock-Based Compensation growth rates for Compass Pathways PLC have been 31% over the past three years , 43% over the past five years .
